Keros Therapeutics (KROS) Liabilities and Shareholders Equity (2019 - 2025)

Keros Therapeutics has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $338.0 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 45.12% year-over-year to $338.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.6 billion (up 22.78% YoY), and the FY2025 full-year result was $338.0 million, down 45.12% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $338.0 million, down from $742.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $784.6 million in Q1 2025, with the low at $226.7 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $410.2 million across 5 years, with a median of $347.2 million in 2023.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 325.35% — and 2025, when it plunged 45.12%.
• Keros Therapeutics' Liabilities and Shareholders Equity stood at $255.3 million in 2021, then rose by 20.19% to $306.8 million in 2022, then advanced by 20.62% to $370.0 million in 2023, then jumped by 66.44% to $615.9 million in 2024, then sank by 45.12% to $338.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $338.0 million (Q4 2025), $742.8 million (Q3 2025), and $757.2 million (Q2 2025), per Business Quant data.